Skip to main content
[Preprint]. 2023 Nov 23:2023.11.23.568486. [Version 1] doi: 10.1101/2023.11.23.568486

Fig 3. CAPE and resveratrol ablate phosphorylation of FAK at Y576.

Fig 3.

(A) Graph shows results from a Kinetworks Phospho-Site screen (KPSS 7.0), in which phosphorylation levels of each of the indicated residues (in parentheses) were quantified in CAPE- and DMSO-treated BECs after a 15-min infection with UTI89. Differences between samples are presented as percentages of the DMSO-treated, UTI89-infected controls: [(CAPE-treated – DMSO-treated)/DMSO-treated * 100]. Shaded areas denote relative changes of 25% or less, and the red bar highlights FAK(Y576) as the phospho-site most altered by CAPE treatment in this analysis (B and C) BECs were treated with carrier alone (0.1% DMSO), CAPE (25 μg/mL), EGCG (25 μg/mL), catechin (25 μg/mL), or resveratrol (22.9 μg/mL) for 1 h prior to a 15-min infection with UTI89 in the continued presence of each reagent. BEC lysates were then collected, resolved by SDS-PAGE, and probed by western blot analysis to assess (B) pFAK(Y576) and (C) pFAK(Y397) levels relative to total FAK in each sample.